1.23

22.64% -0.36

After Hours: 1.23

Traws Pharma Inc (TRAW)

Overview News Price History Discussions Forecast

Traws Pharma Inc stock is traded at $1.23, with a volume of 1.52M. It is down -22.64% in the last 24 hours and down -38.50% over the past month. Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib.

Previous Close:

$1.59

Open:

$1.44

24h Volume:

1.52M

Relative Volume:

7.55

Market Cap:

$9.83M

Revenue:

$2.85M

Net Income/Loss:

$93.35M

P/E Ratio:

0.0511

EPS:

24.0802

Net Cash Flow:

$-19.47M

1W Performance:

-21.15%

1M Performance:

-38.50%

6M Performance:

-56.54%

1Y Performance:

-42.25%

1-Day Range:

$1.13

$1.4445

1-Week Range:

$1.13

$1.67

52-Week Range:

$0.97

$3.265

Traws Pharma Inc Stock (TRAW) Company Profile

Name

Traws Pharma Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

267-759-3680

Address

12 PENNS TRAIL, NEWTOWN

Employee

Twitter

Next Earnings Date

2026-03-30

Latest SEC Filings

TRAW's Discussions on Twitter

Compare TRAW vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TRAW Traws Pharma Inc	1.23	12.71M	2.85M	93.35M	-19.47M	24.08
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-03-25	Initiated	H.C. Wainwright	Buy
Mar-01-22	Initiated	Ladenburg Thalmann	Buy
May-18-21	Initiated	Guggenheim	Buy
Mar-01-18	Reiterated	H.C. Wainwright	Buy
Jan-17-18	Downgrade	Maxim Group	Buy → Hold
Oct-09-17	Initiated	H.C. Wainwright	Buy
Apr-27-17	Initiated	Laidlaw	Buy
Jul-01-15	Upgrade	Piper Jaffray	Neutral → Overweight
May-05-15	Initiated	H.C. Wainwright	Buy

View All

Traws Pharma Inc Stock (TRAW) Latest News

Traws Pharma Inc (TRAW)

Traws Pharma Inc Stock (TRAW) Company Profile

Compare TRAW vs VRTX, REGN, ARGX, ALNY, ONC

Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades

Traws Pharma Inc Stock (TRAW) Latest News

Traws Pharma (TRAW) Secures $60 Million Financing for Influenza Research - GuruFocus

Traws Pharma (NASDAQ: TRAW) pivots to antivirals amid TXM IND hold - Stock Titan

Traws Pharma Reports 2025 Results, Secures PIPE Financing - TipRanks

TRAWS PHARMA INC (NASDAQ:TRAW) Reports 2025 Earnings Beat Amid Dilutive $60M PIPE Financing and FDA Hold - ChartMill

TRAWS PHARMA ($TRAW) Releases Q4 2025 Earnings - Quiver Quantitative

Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights - The Manila Times

Traws Pharma (NASDAQ: TRAW) raises up to $60M PIPE and funds runway into 2027 - Stock Titan

Traws Pharma, Inc. announced that it has received $10.009423 million in funding - marketscreener.com

Traws Pharma Secures Up to $60 Million PIPE Financing to Advance Influenza Drug Trial in the UK - Minichart

Traws Pharma prices $60M PIPE financing deal to fund UK flu trial - MSN

Traws Pharma secures $10M financing for influenza trial By Investing.com - Investing.com India

Traws Pharma Secures PIPE Financing for Influenza Trial - TipRanks

A $10M cash infusion aims to push Traws flu drug into a UK trial - Stock Titan

Traws Pharma (NASDAQ: TRAW) lines up $10M PIPE plus $50M in warrants - Stock Titan

Traws Pharma Delays 10-K Amid Financing Review - TipRanks

Charles Nolan Parker Net Worth (2026) - GuruFocus

hVIVO Lands Influenza Trial Deal - Vox Markets

hVIVO signs influenza human challenge trial contract with Traws Pharma - Vox Markets

Rate Hike: Should I set a stop loss on Traws Pharma Inc2026 Action & Verified Technical Trade Signals - baoquankhu1.vn

Resistance Check: Can Traws Pharma Inc stock outperform in a bear market2026 Recap & Accurate Entry and Exit Point Alerts - baoquankhu1.vn

Aug Levels: How do insiders feel about Traws Pharma IncEarnings Growth Report & Weekly Setup with ROI Potential - baoquankhu1.vn

Traws Pharma (TRAW) CFO receives new RSU and stock option grants - Stock Titan

Traws Pharma (TRAW) CFO Parker Nolan listed as insider in Form 3 - Stock Titan

Traws Pharma, Inc. Experiences Revision in Its Stock Evaluation Amid Mixed Performance Metrics - Markets Mojo

TRAW PE Ratio & Valuation, Is TRAW Overvalued - Intellectia AI

Traws Pharma Inc. (TRAW) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Traws Pharma (TRAW) delays 2025 Form 10-K, cites financing and going-concern review - Stock Titan

Traws Pharma Forms Golden Cross, Signaling Potential Bullish Breakout Ahead - Markets Mojo

Traws Pharma Inc expected to post a loss of $1.22 a shareEarnings Preview - TradingView

Published on: 2026-03-23 16:58:08 - baoquankhu1.vn

Traws Pharma (TRAW) Expected to Announce Earnings on Monday - Defense World

Aug Weekly: Whats the analyst consensus on Traws Pharma IncMarket Risk Analysis & High Win Rate Trade Tips - baoquankhu1.vn

Traws Pharma reports phase 2 COVID-19 data, flu program update - MSN

12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga

Experimental COVID Pill Shows Edge Over Paxlovid as Traws Hits Key Milestones - MSN

Director at Traws Pharma (TRAW) receives grant of 33,435 stock options - Stock Titan

Traws Pharma (TRAW) director granted 31,258 stock options at $1.60 - Stock Titan

Traws Pharma (TRAW) director granted 33,435 stock options at $1.60 strike - Stock Titan

Traws Pharma (TRAW) awards CEO 231,336 stock options at $1.60 - Stock Titan

Traws Pharma (TRAW) awards 118,367 stock options to Chief Science Officer - Stock Titan

Traws Pharma (TRAW) COO receives grant of 96,899 stock options at $1.60 - Stock Titan

Traws Pharma (TRAW) awards 33,435 stock options to director Jack Stover - Stock Titan

Traws Pharma (TRAW) CMO awarded 108,854 stock options at $1.60 - Stock Titan

Traw Pharma director granted 33,435 stock options | TRAW SEC FilingForm 4 - Stock Titan

Will Traws Pharma Inc. (0T20) stock draw ESG focused fundsWeekly Profit Summary & High Accuracy Investment Signals - Naître et grandir

TRAW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Cash per share of Traws Pharma, Inc. – FWB:0T20 - TradingView

TRAW SEC FilingsTraws Pharma 10-K, 10-Q, 8-K Forms - Stock Titan

Traws Pharma Reports Phase 2 COVID-19 Data, Flu Program Update - MyChesCo

Traws Pharma (NASDAQ:TRAW) Trading Down 11.2% – Here’s What Happened - Defense World

Insider Sell: How much upside does Traws Pharma Inc haveTrade Entry Report & Accurate Intraday Trading Signals - baoquankhu1.vn

Traws Pharma Inc Stock (TRAW) Financials Data

Revenue

Net Income

Cash Flow

EPS

Similar to TRAW